Pliant Total Stockholder Equity from 2010 to 2024

PLRX Stock  USD 13.46  0.48  3.70%   
Pliant Therapeutics Total Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Total Stockholder Equity is likely to outpace its year average in 2024. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2019-03-31
Previous Quarter
392.7 M
Current Value
345.8 M
Quarterly Volatility
151 M
 
Covid
Check Pliant Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pliant Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.3 M, Net Interest Income of 20.2 M or Interest Income of 21.5 M, as well as many indicators such as Price To Sales Ratio of 707, Dividend Yield of 0.0 or PTB Ratio of 2.36. Pliant financial statements analysis is a perfect complement when working with Pliant Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Pliant Therapeutics Correlation against competitors.
For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.

Latest Pliant Therapeutics' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Pliant Therapeutics over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Pliant Therapeutics' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pliant Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Slightly volatile
   Total Stockholder Equity   
       Timeline  

Pliant Total Stockholder Equity Regression Statistics

Arithmetic Mean119,449,053
Geometric Mean12,393,626
Coefficient Of Variation154.29
Mean Deviation155,873,004
Median3,345,000
Standard Deviation184,301,214
Sample Variance33966.9T
Range498.1M
R-Value0.82
Mean Square Error12103.4T
R-Squared0.67
Significance0.0002
Slope33,710,559
Total Sum of Squares475537.1T

Pliant Total Stockholder Equity History

2024497.3 M
2023473.6 M
2022313.3 M
2021199.1 M
2020283.1 M
2019-435 K
2018-882 K

About Pliant Therapeutics Financial Statements

Pliant Therapeutics investors use historical fundamental indicators, such as Pliant Therapeutics' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pliant Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Stockholder Equity473.6 M497.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.